Download Product Insert (PDF)

Product Information

Lorglumide (sodium salt) Item No. 17555

CAS Registry No.: 1021868-76-7 Formal Name: 4-[(3,4-dichlorobenzoyl)amino]-5- (dipentylamino)-5-oxo-pentanoic acid, N monosodium salt O MF: C22H31Cl2N2O4 • Na O FW: 481.4 Cl O- Purity: ≥98% N + O • Na Stability: ≥2 years at -20°C H Supplied as: A crystalline solid Cl

Laboratory Procedures For long term storage, we suggest that lorglumide (sodium salt) be stored as supplied at -20°C. It should be stable for at least two years. Lorglumide (sodium salt) is supplied as a crystalline solid. A stock solution may be made by dissolving the lorglumide (sodium salt) in the solvent of choice. Lorglumide (sodium salt) is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of lorglumide (sodium salt) in these solvents is approximately 1 mg/ml. Lorglumide (sodium salt) is sparingly soluble in aqueous buffers. For maximum solubility in aqueous buffers, lorglumide (sodium salt) should first be dissolved in DMSO and then diluted with the aqueous buffer of choice. Lorglumide (sodium salt) has a solubility of approximately 0.5 mg/ml in a 1:1 solution of DMSO:PBS (pH 7.2) using this method. We do not recommend storing the aqueous solution for more than one day. Cholecystokinin (CCK) is a peptide hormone that, through specific receptors, induces pancreatic growth and enzyme secretion, smooth muscle contraction in the gall bladder and stomach, and modulates feeding and behavior.1-3 Lorglumide is a nonpeptidic antagonist of the CCK A receptor (CCK1; IC50 = 50 nM) that is 60-fold less effective at the CCK B 4 receptor (CCK2; IC50 = 3 µM). It blocks CCK-mediated gut muscle contraction, pancreatic growth, and pancreatic 5-7 8,9 secretion. Lorglumide is commonly used to study the roles of CCK1 in tissues and in animals.

References 1. Sabbatini, M.E., Chen, X., Ernst, S.A., et al. Rap1 activation plays a regulatory role in pancreatic amylase secretion. J. Biol. Chem. (2008). 2. Murphy, K.G. and Bloom, S.R. Gut hormones in the control of appetite. Exp. Physiol. 89(5), 507-516 (2004). 3. Wynne, K., Stanley, S., and Bloom, S. The gut and regulation of body weight. J. Clin. Endocrinol. Metab. 89(6), 2576- 2582 (2004). 4. Makovec, F., Peris, W., Revel, L., et al. Structure-antigastrin activity relationships of new (R)-4-benzamido-5- oxopentanoic acid derivatives. J. Med. Chem. 35(1), 28-38 (1992). 5. Barthó, L., Holzer, P., Lembeck, F., et al. Evaluation of a new and potent cholecystokinin antagonist on motor responses of the guinea-pig intestine. Br. J. Pharmac. 90, 753-761 (1987). 6. Niederau, C., Liddle, R.A., Williams, J.A., et al. Pancreatic growth: Interaction of exogenous cholecystokinin, a protease inhibitor, and a cholecystokinin receptor antagonist in mice. Gut 28, 63-69 (1987). 7. Scarpignato, C., Varga, G., Dobronyi, I., et al. Effect of a new potent CCK antagonist, lorglumide, on caerulein- and bombesin-induced pancreatic secretion and growth in the rat. Br. J. Pharmacol. 96, 661-669 (1989). 8. Gamble, J., Kenny, S., and Dockray, G.J. Plasminogen activator inhibitor (PAI)-1 suppresses inhibition of gastric emptying by cholecystokinin (CCK) in mice. Regul. Pept. 185, 9-13 (2013). Cayman Chemical 9. Lo, C.C., Davidson, W.S., Hibbard, S.K., et al. Intraperitoneal CCK and fourth-intraventricular Apo AIV require both peripheral and NTS CCK1R to reduce food intake in male rats. Endocrinology 155(5), 1700-1707 (2014). Mailing address 1180 E. Ellsworth Road Related Products Ann Arbor, MI 48108 USA For a list of related products please visit: www.caymanchem.com/catalog/17555 Phone WARNING: This product is for laboratory research only: not for administration to humans. Not for human or veterinary (800) 364-9897 diagnostic or therapeutic use. (734) 971-3335

SAFETY DATA Fax This material should be considered hazardous until information to the contrary becomes available. Do not ingest, swallow, or inhale. Do not get in eyes, on skin, or on clothing. Wash thoroughly (734) 971-3640 after handling. This information contains some, but not all, of the information required for the safe and proper use of this material. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution. E-Mail WARRANTY AND LIMITATION OF REMEDY Cayman Chemical Company makes no warranty or guarantee of any kind, whether written or oral, expressed or implied, including without limitation, any warranty of fitness for a particular [email protected] purpose, suitability and merchantability, which extends beyond the description of the chemicals hereof. Cayman warrants only to the original customer that the material will meet our specifications at the time of delivery. Cayman will carry out its delivery obligations with due care and skill. Thus, in no event will Cayman have any obligation or liability, whether in tort (including negligence) or in contract, for Web any direct, indirect, incidental or consequential damages, even if Cayman is informed about their possible existence. This limitation of liability does not apply in the case of intentional acts or negligence of Cayman, its directors or its employees. www.caymanchem.com Buyer’s exclusive remedy and Cayman’s sole liability hereunder shall be limited to a refund of the purchase price, or at Cayman’s option, the replacement, at no cost to Buyer, of all material that does not meet our specifications. Said refund or replacement is conditioned on Buyer giving written notice to Cayman within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material. For further details, please refer to our Warranty and Limitation of Remedy located on our website and in our catalog. Copyright Cayman Chemical Company, 04/30/2015